Perlara
https://perlara.comPerlara: building the YC for rare disease parents
Perlara 1.0 (Feb 2014 - Feb 2019) launched early R&D joint ventures called PerlQuests with highly motivated rare disease families, companies or impact investors. We screened gene-edited patient avatars for repurposable drugs in order to build a predictive R&D engine called ArkBase. We planned to monetize programs based on ArkBase predictions by selectively spinning out asset-centric clinical development NewCos. Perlara 1.5 (March 2019 - April 2020) was the transition to a one-person virtual clinical development company and when the epalrestat and aripiprazole repurposing trials were launched at Mayo Clinic for the treatment of PMM2-CDG and NGLY1-CDDG, respectively. Perlara 2.0 (May 2020 --> The first decentralized and distributed biotech
Total Open and Closed Positions
Total open positions, and positions newly closed since the previous update
Department Headcount Over Time
Open positions per department · top 6 at any point in the window
Newly Opened and Closed Positions
Position Churn Rate
Positions closed within 14 days of opening · a high rate suggests posting instability — duplicates, pulled listings, or roles filled through internal or off-market channels
Time-to-Fill Distribution
Days from open to close · closed positions only
Salary Trend Over Time
Monthly median base salary · USD · annualized · p25/p75 dashed
Salary Range by Department
Employment Type
Technical vs. Non-technical
Open positions · by department
Top Roles by Department
Seniority Mix
Derived from job title keywords
Equity Range by Department
Top Skills
Top Tech Stacks
Skills Trend
Change in share of postings · recent 3 months vs. prior 3 months
Tech Stack Evolution
Positions opened per month · top 5 technologies